Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Tevogen Bio Holdings Inc (TVGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TVGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -34.52% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 210.06M USD | Price to earnings Ratio 3.09 | 1Y Target Price 10 |
Price to earnings Ratio 3.09 | 1Y Target Price 10 | ||
Volume (30-day avg) 509397 | Beta -1.05 | 52 Weeks Range 0.26 - 4.78 | Updated Date 04/1/2025 |
52 Weeks Range 0.26 - 4.78 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.35 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -542.18% | Return on Equity (TTM) - |
Valuation
Trailing PE 3.09 | Forward PE - | Enterprise Value 196489195 | Price to Sales(TTM) - |
Enterprise Value 196489195 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 3.77 | Shares Outstanding 175051008 | Shares Floating 13914824 |
Shares Outstanding 175051008 | Shares Floating 13914824 | ||
Percent Insiders 91.35 | Percent Institutions 1.47 |
Analyst Ratings
Rating - | Target Price 4.2 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tevogen Bio Holdings Inc
Company Overview
History and Background
Tevogen Bio Holdings Inc. is a biotechnology company focused on developing off-the-shelf, allogeneic T cell immunotherapies for cancer, viral infections, and autoimmune diseases. Founded recently, it aims to revolutionize immunotherapy by addressing limitations of existing personalized approaches.
Core Business Areas
- Immunotherapy Development: Development of allogeneic T cell immunotherapies targeting specific diseases using proprietary ExacTargu2122 technology.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its T cell therapy products.
- Manufacturing: Developing and optimizing manufacturing processes for its T cell therapy products.
Leadership and Structure
Details on leadership and organizational structure are generally not publicly available for privately held entities like Tevogen Bio Holdings Inc. without further information.
Top Products and Market Share
Key Offerings
- TVGN-489: An allogeneic cytotoxic CD8+ T lymphocyte (CTL) product candidate for the treatment of COVID-19, with plans for clinical trials. Competitors: Gilead's Veklury, Pfizer's Paxlovid.
- ExacTargu2122 technology: A proprietary technology platform for developing targeted T-cell therapies. Competitors: CAR-T cell therapies (Novartis' Kymriah, Gilead's Yescarta), TCR-based therapies.
Market Dynamics
Industry Overview
The immunotherapy market is rapidly growing, driven by advancements in cancer treatment and the increasing prevalence of autoimmune and infectious diseases. Allogeneic cell therapies are gaining traction due to their scalability and cost-effectiveness compared to autologous therapies.
Positioning
Tevogen Bio Holdings Inc. aims to position itself as a leader in the allogeneic T cell immunotherapy space, focusing on off-the-shelf solutions with enhanced targeting capabilities.
Total Addressable Market (TAM)
The global immunotherapy market is projected to reach hundreds of billions of USD within the next decade. Tevogen Bio Holdings Inc. targets a portion of this market with its allogeneic T cell therapy platform.
Upturn SWOT Analysis
Strengths
- Proprietary ExacTargu2122 technology
- Potential for off-the-shelf allogeneic therapies
- Focus on unmet medical needs in cancer, viral infections, and autoimmune diseases
Weaknesses
- Early stage of development
- Limited clinical data
- Dependence on successful clinical trials
- Financial sustainability
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in T cell engineering
- Growing demand for allogeneic cell therapies
Threats
- Competition from established immunotherapy companies
- Regulatory hurdles
- Clinical trial failures
- Manufacturing challenges
- High cost of development
Competitors and Market Share
Key Competitors
- GILD
- PFE
- NVS
- KITE (GILD Subsidiary)
Competitive Landscape
Tevogen Bio Holdings Inc. is an early-stage player in a competitive market dominated by larger pharmaceutical companies. Its success depends on demonstrating clinical efficacy and establishing manufacturing capabilities.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: N/A
Future Projections: Future growth depends on clinical trial results and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing TVGN-489 to clinical trials and expanding the ExacTargu2122 technology platform.
Summary
Tevogen Bio Holdings Inc. is a high-risk, high-reward biotechnology company focused on developing allogeneic T cell therapies. Its proprietary ExacTargu2122 technology offers potential advantages, but the company faces significant challenges related to clinical development, regulatory approval, and competition from established players. Success will depend on positive clinical trial outcomes and securing partnerships or funding to support its operations.
Similar Companies
BEAM
Beam Therapeutics Inc
BEAM
Beam Therapeutics Inc
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
EDIT
Editas Medicine Inc
EDIT
Editas Medicine Inc
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
NVS
Novartis AG ADR
NVS
Novartis AG ADR
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Company Website
- Press Releases
- Industry Reports
- Analyst Reports (where available)
Disclaimers:
This analysis is based on limited publicly available information and should not be considered financial advice. Market share estimates are approximate. Ratings are AI generated, may have some innacurracies, and may need human oversight.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tevogen Bio Holdings Inc
Exchange NASDAQ | Headquaters Warren, NJ, United States | ||
IPO Launch date 2024-02-15 | Co-Founder, CEO & Chairman Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://tevogen.com |
Full time employees - | Website https://tevogen.com | ||
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.